Dr K Hellmann (Cancer Chemotherapy Department, Imperial Cancer Research Fund, Lincoln's Inn Fields, London WC2A 3PX) Effect of ICRF 159 on Immune Responses ICRF 159, (±)-l, 2-bis (3, 5-dioxopiperazin-1-yl) propane, is a member of a new class of potent cytostatic agents, the bisdioxopiperazines, which inhibit the division of normal and malignant cells (Creighton et al. 1969) . These compounds might therefore be expected to inhibit the emergence of immunocompetent cells and thus have immunosuppressant activity. It seemed of some importance to study this problem since ICRF 159 has been used in clinical trials as an antitumour agent for some two years During this time, however, no complication in any patient has been observed which could be attributed to immunosuppression by the drug (with the possible exception of one acute leukmmic patient who developed sudden and severe pyrexia of unknown origin).
ICRF 159 has a number of properties which give it some clinical as well as considerable experimental interest. It is first of all a new type of chemical structure to exhibit antimitotic properties. It is active against a variety of experimentally transplanted tumours, the activity being precise and consistent so that with some solid tumours good dose responses can be obtained repeatedly. It appears to stop cell division by interfering with an as yet undefined biochemical process or processes at the end of the G2 or beginning of the mitotic phase of the cell generation cycle (Sharpe et al. 1970 , Hellmann & Field 1970 , a point at which none of the anticancer agents in general use today are known to act. It is not surprising, therefore, that it does not cross-react with any of them. On the contrary, it appears to potentiate the activity of most of them . It is also the first known agent to inhibit completely the hematogenous spread of experimental metastases without stopping the growth of the primary tumour (Hellmann & Burrage 1969) . The compound appears to prevent the escape of malignant cells from the primary growth (Salsbury et al. 1970 ). All these properties made investigation of its effect in the clinic and on immunity desirable.
Immunosuppression of cell-mediated immunity was examined by testing the effect of ICRF 159 on the survival of skin allografts. Neither ICRF 159 nor ICRF 154, a potent analogue of ICRF 159, significantly prolonged the median survival times of skin transplants from C57B1 female mice to C3H/He female recipients. ICRF 154 seemed to be without any effect even at maximum tolerated doses whereas ICRF 159 slightly prolonged graft survival, but only at doses five times those required for tumour inhibition. These doses were, however, toxic in that at least one-third of the animals died before completion of the experiments.
Suppression of humoral immunity has been examined in random bred Swiss Schneider (SN) mice by two methods (Tucker 1972 ): Jerne's technique of localized htmolysis by spleen cells (PFC) dispersed in agar (Jerne et al. 1963 ) and the estimation of antibody titre by antigen-binding capacity (Brownstone et al. 1966 ) following both 'priming' and 'boosting' injections of bovine serum albumin (BSA) .
Variation in the timing and amounts of the doses of the drugs (administered intraperitoneally) showed that, in both test systems, there was a dose-dependent immunosuppressive effect by ICRF 154 and 159. In five out of six experiments, the drugs given 48 hours before the antigen significantly reduced the appearance of PFC in the spleen, but not when given either together with or 7, 24 and 72 hours before the antigen. When the drugs were given at the same times after antigen, the tendency was for inhibition of PFC to increase progressively up to 48 hours. At 72 hours they were as effective as at 48 hours.
This apparent greater sensitivity to inhibition when drugs are given at 48 hours before antigen is an unusual finding and without more evidence is difficult to explain. One possibility could be that the inhibition is mediated through a reduction of a dividing population of 'uncommitted' precursors of the immunologically competent antibody forming spleen cells.
Both drugs also significantly inhibit the normally very efficient primary immunization brought about by an injection of 800 pg BSA combined with killed B. pertussis organisms as adjuvant. This suppression again is dose dependent and also depends upon the length of time that drugs are administered. The greater the dose of the drugs and the longer they are given, the greater the effect. The effect on the secondary response to BSA was much less obvious, although some suppression could be detected.
It appears, therefore, that ICRF 159 has little, if any, effect on cell-mediated immunity, but is a potent depressor of humoral immunity. These findings are consistent with the histopathological observations following chronic toxicity studies which have shown gross lymphoid depletion in the thymus and spleen but only moderate to slight depletion of lymphoid elements in the lymph nodes of rats following chronic administration of the two compounds.
The poor immunosuppressive effect on cellmediated immunity, demonstrated by failure of ICRF 159 to increase significantly the survival of skin allografts, is being further investigated to see whether this lack of effect also applies to other manifestations of cell-mediated immunity such as delayed hypersensitivity and the graft-versus-host reaction. Preliminary results appear to indicate that the drug is more effectively immunosuppressive under these conditions. Suppression of cell-mediated immunity by anticancer agents may be of considerable clinical significance, since there is some evidence (James & Salsbury 1972 , Lewis et al. 1969 ) that the spread of strongly antigenic tumours may be controlled by this form of immunity. It seems possible, therefore, that where an anticancer agent is not successful in eliminating the last few cancer cells, but only depresses the mechanism that prevents their dissemination, spread of the disease may soon follow treatment.
Although ICRF 159 has, in common with most anticancer agents, an immunosuppressive effect, this is (a) only moderate on cell-mediated immunity and (b) counterbalanced by the fact that the drug itself has an antimetastatic effect by preventing the escape of malignant cells into the bloodstream.
Examination of the peripheral blood of mice following tumour implants has shown that considerable numbers of atypical mononuclear cells appear in the blood within 48 hours of tumour implantation (Salsbury, unpublished) . These cells are pyroninophilic, their appearance is inhibited by antithymocyte serum and the time course of their appearance is consistent with the assumption that they may be immunoblasts. They are greatly diminished in animals treated with ICRF 159.
Immunoblasts have been widely implicated as the effector cells for cell-mediated immunity in the homograft reaction and it may be that they also play a part in preventing the establishment of tumours and in controlling their spread. If they do, the depression of their numbers by ICRF 159 following tumour implantation contrasts strangely with the weak immunosuppressive effect of the drug on cell-mediated immunity following skin allograft transplantation. It leads one to suppose that there must be different populations of immunoblasts with differential sensitivities involved in cell-mediated immunity evoked by different types of antigens.
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Immunosuppressive Action of L-Asparaginase
The discovery that the enzyme L-asparaginase is immunosuppressive followed directly from the use of this material in the treatment of acute leukiemia. Some leukaemia cells require exogenous asparagine for survival and hence the depletion of circulating asparagine by the administration of, L-asparaginase results in the death of these leukiemia cells. L-asparaginase seemed at one time to be the first truly specific antineoplastic agent, for no other cell renewal system, such as the bone marrow or the gastrointestinal mucosa, appeared to require exogenous asparagine for normal function. In practice, the administration of the enzyme L-asparaginase gave rise to toxic side-effects; these were not as serious as found with the normal cytotoxic agents and, in particular, unlike almost all other anticancer agents, there was no effect on the cells in the blood. The reason for this toxicity is not quite clear since the only practical source of L-asparaginase is from bacteria and it is with such preparations that the side-effects have been observed. The various bacterial L-asparaginases also have glutaminase activity and it is possible that some of the toxic side-effects are due to the hydrolysis of glutamine or to other effects following from the injection of large amounts of bacterial protein. In theory, this problem ought to be resolved by using L-asparaginase from mammalian sources and in particular from the serum of
